Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer [PDF]
British Journal of Cancer, 2003 Angiogenesis is critical for the growth and metastasis of endometrial cancer and is therefore an important therapeutic target. Vascular endothelial growth factor-A (VEGF-A) is a key molecule in angiogenesis, but the identification of related molecules and the angiopoietins suggests a more complex picture. We investigated the presence of transcripts for
C M Holland +3 more
openalex +5 more sources
Simultaneous FTIR and Raman Spectroscopy in Endometrial Atypical Hyperplasia and Cancer [PDF]
International Journal of Molecular Sciences, 2020 Currently, endometrial carcinoma (EC) is the most common genital cancer in high-income countries. Some types of endometrial hyperplasia (EH) may be progressing to this malignancy. The diagnosis of EC and EH is based on time consuming histopathology evaluation, which is subjective and causes discrepancies in reassessment.
Edyta Barnaś +8 more
openalex +4 more sources
Progression of fertility-sparing treatment for atypical endometrial hyperplasia in a woman with lynch syndrome: a case report and review of the literature. [PDF]
Front OncolHsu YT, Chen CH.
europepmc +2 more sources
Laparoscopic Surgery for Atypical Endometrial Hyperplasia with Awareness Regarding the Possibility of Endometrial Cancer. [PDF]
Gynecol Minim Invasive Ther, 2023 Objectives: Although atypical endometrial hyperplasia (AEH) is considered a precancerous disease, the frequency with which AEH and endometrial cancer (EC) coexist is not low. Broadly, total laparoscopic hysterectomy (TLH) is performed for treating AEH; however, it is unclear what perioperative precautions need to be taken. This
Kamii M +5 more
europepmc +4 more sources
Endometrial Atypical Hyperplasia and Risk of Endometrial Cancer [PDF]
DiagnosticsEndometrial atypical hyperplasia (EAH) is a premalignant condition with a substantial risk of progression to endometrial cancer (EC), with the endometrioid subtype being the most common. EAH is characterized by abnormal endometrial gland proliferation and cellular atypia, often resulting from prolonged unopposed estrogen exposure.
Andy Shau–Bin Chou +2 more
openalex +3 more sources
A multi-centre randomised controlled trial comparing megestrol acetate to levonorgestrel-intrauterine system in fertility sparing treatment of atypical endometrial hyperplasia. [PDF]
J Assist Reprod GenetGoh CSY +8 more
europepmc +2 more sources
Fertility-sparing re-treatment for endometrial cancer and atypical endometrial hyperplasia patients with progestin-resistance: a retrospective analysis of 61 cases. [PDF]
World J Surg OncolChen J, Cao D.
europepmc +3 more sources
The reproductive function of patients with prior atypical endometrial hyperplasia and endometrial cancer treatment: cohort study [PDF]
Гинекология, 2022 Aim. To define the management of realization of reproductive function implementation in patients experienced atypical endometrial hyperplasia and endometrial cancer IA stage. Materials and methods. 150 patients aged 2142 years were included.
Lana G. Dzhanashvili +4 more
doaj +1 more source
GnRH-a-based fertility-sparing treatment of atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EC) patients: a multicenter, open-label, randomized designed clinical trial protocol. [PDF]
TrialsLiu Q, Zhou H, Yu M, Cao D, Yang J.
europepmc +2 more sources
Comparative effects of progestin-based combination therapy for endometrial cancer or atypical endometrial hyperplasia: a systematic review and network meta-analysis. [PDF]
Front OncolCui J, Zhao YC, She LZ, Wang TJ.
europepmc +3 more sources